Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
about
A functional and regulatory network associated with PIP expression in human breast cancerLong-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testingPlasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicinePrognostic significance of deregulated dicer expression in breast cancerNode-Negative Breast Cancer: Which Patients Should Be Treated?Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Breast cancer biomarkers and molecular medicine: part II.Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.DNA aneuploidy and breast cancer: a meta-analysis of 141,163 cases.Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patientsAdjuvant Systemic Therapy, Quo Vadis? Patient Selection, Prognostic and Predictive Factors.Very young women (<35 years) with operable breast cancer: features of disease at presentation.Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines.Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
P2860
Q21143857-352E3301-C6C0-4D1E-9485-2B88D74889FDQ24797752-84741C7A-8604-4622-AB16-48899890434EQ28067626-90ED483B-EF9A-450F-9472-89FB1F29D62CQ28393448-80AC9BD1-101D-4EAC-B18A-9FFD5F021DC2Q34284270-D486894C-6F9E-4F6F-9022-43DBD6BF6297Q34433731-9FC574AA-A54F-454B-BAB4-B017A5D64005Q35580701-4EA0A618-9627-4796-9A5A-DB0DFE638DEDQ35680309-B6324775-07E1-407E-93EC-1A84CAE17080Q35990029-03118A40-D080-4212-8FB0-9A92E2A01CA1Q36490382-173FE0AB-E832-4F41-8792-D2FC9053EC48Q36609527-3A29E2FD-B3D6-4DCF-8BE6-C8E5DED86BDAQ37645007-CA49E8D8-7C00-4006-A1EF-34AAF9090447Q37671450-6113470A-7FAB-40C1-91DE-39396766C9F8Q42253254-56E71763-074A-44B2-8AEC-92496678D0BEQ43910363-8EB35E4F-BBAC-4040-90FD-8B81E6F5C2EDQ47435359-32853321-DEF2-4CFE-9F99-A6DF6E5B8285Q52959904-9C308169-D68A-4178-89DA-29767B9F6376
P2860
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@ast
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@en
type
label
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@ast
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@en
prefLabel
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@ast
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@en
P2093
P2860
P356
P1476
Risk-group discrimination in n ...... kers: 6-year median follow-up.
@en
P2093
Thomssen C
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690373
P407
P577
1999-05-01T00:00:00Z